CapsoVision (CV) vs Electromed (ELMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CapsoVision (CV) has outperformed Electromed (ELMD) over the past year, gaining 16.8% versus a loss of 11.3%. CapsoVision is the larger company by market cap ($327.6 million vs $187.8 million), about 1.7 times the size. Electromed converts more of its revenue into profit, with a net margin of 15.3% versus -186.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CV | ELMD |
|---|---|---|
| Share price | $6.11 | $22.98 |
| Market cap | $327.56M | $187.84M |
| 1-day change | -3.17% | -1.20% |
| YTD return | -42.84% | -21.09% |
| 1-year return | +16.83% | -11.31% |
| 5-year return | — | +99.13% |
| P/E ratio (TTM) | — | 16.65 |
| Forward P/E | — | 37.67 |
| EPS (TTM) | $-0.42 | $1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.55M | $73.78M |
| Revenue growth (YoY) | +15.29% | +15.28% |
| Net income (latest FY) | $-25.32M | $11.30M |
| Gross margin | 52.92% | 78.54% |
| Operating margin | -188.25% | 18.82% |
| Net margin | -186.77% | 15.32% |
| 52-week high | $15.37 | $47.40 |
| 52-week low | $4.50 | $22.67 |
| Distance from 52-week high | -60.25% | -51.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +55.48% | +111.05% |
| Average volume | 173.59K | 83.59K |
| Shares outstanding | 53.61M | 8.17M |
| Employees | 99 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CV has outperformed ELMD by 28.1 percentage points over the past year.
- Electromed is more profitable, keeping 15.3 cents of every revenue dollar as net income versus -186.8 cents for CapsoVision.
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
About Electromed
ELMD stock →Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 195 employees
CV vs ELMD FAQ
Which is bigger, CapsoVision or Electromed?
CapsoVision (CV) is larger, with a market capitalization of $327.56M compared with $187.84M for Electromed (ELMD).
Which stock has performed better over the past year, CV or ELMD?
CV returned +16.83% over the past 12 months, compared with -11.31% for ELMD (price return, excluding dividends). Past performance does not predict future results.
Are CapsoVision and Electromed in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.